SC
VTGN icon

Stempoint Capital’s VistaGen Therapeutics VTGN Stock Holding History

Stempoint Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Hold
616,749
– – ﹤0.01% 83
2026
Q1 		$58.2K Hold
616,749
– – 0.01% 78
2025
Q4 		$142K Sell
616,749
-1,871,936
-75% -$6.76M 0.02% 76
2025
Q3 		$7.75M Buy
2,488,685
+75,431
+3% +$225K 1.55% 20
2025
Q2 		$4.12M Buy
2,413,254
+46,700
+2% +$106K 1.32% 25
2025
Q1 		$5.11M Buy
2,366,554
+38,062
+2% +$108K 1.63% 25
2024
Q4 		$5.95M Buy
2,328,492
+481,700
+26% +$1.36M 1.48% 25
2024
Q3 		$4.9M Sell
1,846,792
-1,790
-0.1% -$6.11K 1.47% 22
2024
Q2 		$5.85M Hold
1,848,582
– – 1.72% 17
2024
Q1 		$9.29M Buy
1,848,582
+58,400
+3% +$281K 2.46% 14
2023
Q4 		$8.76M Buy
+1,790,182
New +$6.77M 2.34% 17

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Stempoint Capital's VTGN Position: Q2 2026 in Review

Stempoint Capital held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 616,749 shares worth $17.3K. The position accounts for ﹤0.01% of the portfolio, ranked #83.

Stempoint Capital first reported a position in VTGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $9.29M in Q1 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Stempoint Capital held 616,749 shares of VistaGen Therapeutics worth $17.3K as of Q2 2026.
  • Stempoint Capital left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Stempoint Capital's portfolio in Q2 2026, its #83 holding.
  • Stempoint Capital first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Stempoint Capital's VistaGen Therapeutics position peaked at $9.29M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.